C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
Multiple 2024 Clinical Updates Expected, Including Data from the Ongoing CFT7455 and CFT1946 Phase 1 Dose Escalation Trials
Prioritization of CFT7455, CFT1946, Discovery Collaborations and Focused Discovery Research Efforts Results in Workforce Reduction of Approximately 30%
Related news for (CCCC)
- C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
- Today’s Top Performers: MoBot’s Market Review 10/16/25 10:00 AM
- 24/7 Market News Snapshot 16 October, 2025 – C4 Therapeutics, Inc. (NASDAQ:CCCC)
- C4 Therapeutics Teams Up with Pfizer on New Myeloma Combo Trial
- From SaaS to Semis: Market Signals Big Moves Ahead
